NCT07180160View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

March 31, 2028

Conditions
Advanced Breast Cancer
Interventions
DRUG

QL1706

QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).

DRUG

CDK4/6 inhibitor

palbociclib OR ribociclib OR abemaciclib OR dalpiciclib

DRUG

Fulvestrant

SERD

Trial Locations (1)

200127

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Wenjin Yin

OTHER